27999011|t|Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591
27999011|a|Rifampicin, a potent first-line TB drug of the rifamycin group, shows only little activity against the emerging pathogen Mycobacterium abscessus. Reportedly, bacterial resistance to rifampicin is associated with polymorphisms in the target gene rpoB or the presence of enzymes that modify and thereby inactivate rifampicin. The aim of this study was to investigate the role of the MAB_0591 (arrMab)-encoded rifampicin ADP-ribosyltransferase (Arr_Mab) in innate high-level rifampicin resistance in M. abscessus. Recombinant Escherichia coli and Mycobacterium tuberculosis strains expressing MAB_0591 were generated, as was an M. abscessus deletion mutant deficient for MAB_0591. MIC assays were used to study susceptibility to rifampicin and C25 carbamate -modified rifamycin derivatives. Heterologous expression of MAB_0591 conferred rifampicin resistance to E. coli and M. tuberculosis Rifamycin MIC values were consistently lower for the M. abscessus ΔarrMab mutant as compared with the M. abscessus ATCC 19977 parental type strain. The rifamycin WT phenotype was restored after complementation of the M. abscessus ΔarrMab mutant with arrMab Further MIC data demonstrated that a C25 modification increases rifamycin activity in WT M. abscessus However, MIC studies in the M. abscessus ΔarrMab mutant suggest that C25 modified rifamycins are still subject to modification by Arr_Mab CONCLUSIONS: Our findings identify Arr_Mab as the major innate rifamycin resistance determinant of M. abscessus. Our data also indicate that Arr_Mab -mediated rifamycin resistance in M. abscessus can only in part be overcome by C25 carbamate modification.
27999011	0	9	Intrinsic	T082	C0205102
27999011	10	19	rifamycin	T109,T195	C0035609
27999011	20	30	resistance	T032	C0949285
27999011	34	57	Mycobacterium abscessus	T007	C0445910
27999011	73	95	ADP-ribosyltransferase	T116,T126	C0085748
27999011	96	104	MAB_0591	T028	C0017337
27999011	105	115	Rifampicin	T109,T195	C0035608
27999011	137	144	TB drug	T121	C0013227
27999011	152	167	rifamycin group	T109,T195	C0035609
27999011	187	195	activity	T169	C0599112
27999011	217	225	pathogen	T001	C0450254
27999011	226	249	Mycobacterium abscessus	T007	C0445910
27999011	263	283	bacterial resistance	T046	C0151521
27999011	287	297	rifampicin	T109,T195	C0035608
27999011	317	330	polymorphisms	T045	C0032529
27999011	345	354	gene rpoB	T028	C0017337
27999011	374	381	enzymes	T116,T126	C0014442
27999011	417	427	rifampicin	T109,T195	C0035608
27999011	433	436	aim	T078	C1947946
27999011	486	494	MAB_0591	T028	C0017337
27999011	496	502	arrMab	T028	C0017337
27999011	512	522	rifampicin	T109,T195	C0035608
27999011	523	545	ADP-ribosyltransferase	T116,T126	C0085748
27999011	547	554	Arr_Mab	T116,T126	C0085748
27999011	577	587	rifampicin	T109,T195	C0035608
27999011	588	598	resistance	T032	C0949285
27999011	602	614	M. abscessus	T007	C0445910
27999011	616	627	Recombinant	T001	C1514798
27999011	628	644	Escherichia coli	T007	C0014834
27999011	649	675	Mycobacterium tuberculosis	T007	C0026926
27999011	676	683	strains	T001	C1518614
27999011	684	694	expressing	T045	C0017262
27999011	695	703	MAB_0591	T028	C0017337
27999011	730	742	M. abscessus	T007	C0445910
27999011	743	758	deletion mutant	T045	C1511760
27999011	759	768	deficient	T169	C0011155
27999011	773	781	MAB_0591	T028	C0017337
27999011	783	793	MIC assays	T059	C1510438
27999011	813	827	susceptibility	T169	C1264642
27999011	831	841	rifampicin	T109,T195	C0035608
27999011	846	859	C25 carbamate	T109	C0006948
27999011	870	891	rifamycin derivatives	T109,T195	C0035609
27999011	893	905	Heterologous	T080	C0439860
27999011	906	916	expression	T045	C0017262
27999011	920	928	MAB_0591	T028	C0017337
27999011	939	949	rifampicin	T109,T195	C0035608
27999011	950	960	resistance	T032	C0949285
27999011	964	971	E. coli	T007	C0014834
27999011	976	991	M. tuberculosis	T007	C0026926
27999011	992	1001	Rifamycin	T109,T195	C0035609
27999011	1002	1012	MIC values	T034	C1304747
27999011	1045	1057	M. abscessus	T007	C0445910
27999011	1058	1072	ΔarrMab mutant	T028	C0678941
27999011	1076	1084	compared	T052	C1707455
27999011	1094	1117	M. abscessus ATCC 19977	T007	C0445910
27999011	1118	1138	parental type strain	T001	C1518614
27999011	1144	1153	rifamycin	T109,T195	C0035609
27999011	1154	1156	WT	T028	C1883559
27999011	1157	1166	phenotype	T032	C0031437
27999011	1186	1201	complementation	T045	C0178654
27999011	1209	1221	M. abscessus	T007	C0445910
27999011	1222	1236	ΔarrMab mutant	T028	C0678941
27999011	1242	1248	arrMab	T116,T126	C0085748
27999011	1257	1265	MIC data	T034	C1304747
27999011	1286	1289	C25	T109	C0006948
27999011	1290	1302	modification	T033	C3840684
27999011	1313	1322	rifamycin	T109,T195	C0035609
27999011	1323	1331	activity	T169	C0599112
27999011	1335	1337	WT	T028	C1883559
27999011	1338	1350	M. abscessus	T007	C0445910
27999011	1360	1371	MIC studies	T062	C0681814
27999011	1379	1391	M. abscessus	T007	C0445910
27999011	1392	1406	ΔarrMab mutant	T028	C0678941
27999011	1420	1423	C25	T109	C0006948
27999011	1433	1443	rifamycins	T109,T195	C0035609
27999011	1465	1477	modification	T033	C3840684
27999011	1481	1488	Arr_Mab	T116,T126	C0085748
27999011	1524	1531	Arr_Mab	T116,T126	C0085748
27999011	1552	1561	rifamycin	T109,T195	C0035609
27999011	1562	1572	resistance	T032	C0949285
27999011	1588	1600	M. abscessus	T007	C0445910
27999011	1630	1637	Arr_Mab	T116,T126	C0085748
27999011	1648	1657	rifamycin	T109,T195	C0035609
27999011	1658	1668	resistance	T032	C0949285
27999011	1672	1684	M. abscessus	T007	C0445910
27999011	1717	1730	C25 carbamate	T109	C0006948
27999011	1731	1743	modification	T033	C3840684